<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500357</url>
  </required_header>
  <id_info>
    <org_study_id>6115A1-3009</org_study_id>
    <nct_id>NCT00500357</nct_id>
  </id_info>
  <brief_title>Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects</brief_title>
  <official_title>A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of a Subsequent Dose of 13-valent Pneumococcal Conjugate Vaccine Administered to One Group of Individuals Who Participated in Study 6115A1-500</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a follow-up study to the core study NCT00269672 (6115A1-500). This study will further
      evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate
      vaccine (13vPnC) when administered to subjects who have already received one dose of 13vPnC,
      and one dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) one year later. This
      study will determine if a subsequent dose of 13vPnC one year later results in similar or
      greater immune response (body's ability to protect against disease) than that measured after
      the initial dose of 13vPnC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)</measure>
    <time_frame>Month 1 / Year 0 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)</measure>
    <time_frame>Month 1 / Year 1 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)</measure>
    <time_frame>Month 1 / Year 0 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)</time_frame>
    <description>Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)</measure>
    <time_frame>Month 1 / Year 1 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)</time_frame>
    <description>Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
  </secondary_outcome>
  <enrollment type="Actual">105</enrollment>
  <condition>Vaccines, Pneumococcal Conjugate Vaccine</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>1 dose 13vPnC</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Previous participant of study 6115A1-500 and received 13vPnC +AlPO4 / 23vPS

          -  Generally healthy male or female adults 65 years of age or older

          -  Available for the duration of the trial - approximately 1 month

          -  No history of severe adverse reaction associated with a vaccine

               -  MMSE score less than or equal to 21 was an exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Amanzimtoti</city>
        <zip>4126</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bishop Lavis</city>
        <zip>7490</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <zip>9317</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brits</city>
        <zip>0250</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <zip>7941</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <zip>7945</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lenasia</city>
        <zip>1827</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paarl</city>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parow</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parys</city>
        <zip>9585</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <zip>0082</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <zip>0183</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottburgh South</city>
        <zip>4180</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vanderbijlpark</city>
        <zip>1911</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2007</study_first_posted>
  <results_first_submitted>January 21, 2011</results_first_submitted>
  <results_first_submitted_qc>January 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2011</results_first_posted>
  <disposition_first_submitted>January 21, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 24, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 28, 2009</disposition_first_posted>
  <last_update_submitted>April 15, 2011</last_update_submitted>
  <last_update_submitted_qc>April 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wyeth (Registry Contact: Clinical Trial Registry Specialist)</name_title>
    <organization>Wyeth</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>915 participants were enrolled in core study NCT00269672 (6115A1-500); 914 participants received 13-valent pneumococcal conjugate vaccine plus or minus aluminum phosphate (13vPnC+AlPO4 or 13vPnC-AlPO4) or 23-valent pneumococcal polysaccharide vaccine (23vPS) in Year 0 (Vaccination 1 [Vax 1]) followed by 13vPnC+AlPO4 or 23vPS in Year 1 (Vax 2).</recruitment_details>
      <pre_assignment_details>105 participants from the core study NCT00269672 (6115A1-500) who had received 13vPnC+AlPO4 (13vPnC) followed by 23vPS enrolled in the follow-up study NCT00500357 (6115A1-3009) 1 year after completion of the core study and received a subsequent 13vPnC dose at Year 2 (Vax 3).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC (Vax 3 Follow-up / NCT00500357)</title>
          <description>Administered 13vPnC 0.5 milliliters (mL) intramuscularly (IM) at Year 0 (Vaccination 1 [Vax 1]) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672 (6115A1-500). Administered 13vPnC 0.5 mL IM at Year 2 (Vax 3) in follow-up study/NCT00500357 (6115A1-3009).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 13vPnC (Vax 3)</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable Immunogenicity Population</title>
              <participants_list>
                <participants group_id="P1" count="98">Administered Vax 1 and Vax 2 in study 6115A1-500; Vax 3 and at least 1 assay result in 6115A1-3009.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC (Vax 3 Follow-up / NCT00500357)</title>
          <description>Administered 13vPnC 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672 (6115A1-500). Administered 13vPnC 0.5 mL IM at Year 2 (Vax 3) in follow-up study/NCT00500357 (6115A1-3009).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.8" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>Month 1 / Year 0 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)</time_frame>
        <population>Evaluable Immunogenicity population includes participants from the evaluable immunogenicity population for Vax 1 and Vax 2 in the core study/NCT00269672, received 13vPnC in follow-up study/NCT00500357, and had at least 1 assay result in the follow-up study. N=number of participants with a determinate antibody titer for the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Vax 1 Core Study/NCT00269672)</title>
            <description>13vPnC 0.5 mL IM at Year 0 (Vax 1) in core study/NCT00269672 (6115A1-500).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357)</title>
            <description>13vPnC 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672 (6115A1-500). Administered 13vPnC 0.5mL IM at Year 2 (Vax 3) in follow-up study/NCT00500357 (6115A1-3009).</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable Immunogenicity population includes participants from the evaluable immunogenicity population for Vax 1 and Vax 2 in the core study/NCT00269672, received 13vPnC in follow-up study/NCT00500357, and had at least 1 assay result in the follow-up study. N=number of participants with a determinate antibody titer for the specified serotype.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198" lower_limit="133.7" upper_limit="293.0"/>
                    <measurement group_id="O2" value="78" lower_limit="55.4" upper_limit="108.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" lower_limit="94.2" upper_limit="167.8"/>
                    <measurement group_id="O2" value="104" lower_limit="81.5" upper_limit="132.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2210" lower_limit="1603.5" upper_limit="3045.2"/>
                    <measurement group_id="O2" value="1254" lower_limit="926.6" upper_limit="1695.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413" lower_limit="278.0" upper_limit="614.9"/>
                    <measurement group_id="O2" value="170" lower_limit="119.7" upper_limit="241.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4931" lower_limit="3391.0" upper_limit="7170.8"/>
                    <measurement group_id="O2" value="3158" lower_limit="2369.3" upper_limit="4209.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3251" lower_limit="2105.0" upper_limit="5019.6"/>
                    <measurement group_id="O2" value="2440" lower_limit="1753.2" upper_limit="3395.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="869" lower_limit="540.3" upper_limit="1398.0"/>
                    <measurement group_id="O2" value="353" lower_limit="221.7" upper_limit="561.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="977" lower_limit="588.6" upper_limit="1620.4"/>
                    <measurement group_id="O2" value="247" lower_limit="142.9" upper_limit="426.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="982" lower_limit="676.0" upper_limit="1425.8"/>
                    <measurement group_id="O2" value="550" lower_limit="392.5" upper_limit="769.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2860" lower_limit="1899.9" upper_limit="4304.6"/>
                    <measurement group_id="O2" value="1457" lower_limit="1057.8" upper_limit="2008.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1141" lower_limit="832.4" upper_limit="1564.3"/>
                    <measurement group_id="O2" value="431" lower_limit="340.3" upper_limit="546.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1014" lower_limit="654.4" upper_limit="1572.6"/>
                    <measurement group_id="O2" value="494" lower_limit="341.4" upper_limit="715.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523" lower_limit="315.4" upper_limit="867.7"/>
                    <measurement group_id="O2" value="661" lower_limit="443.6" upper_limit="985.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
            <estimate_desc>Confidence Intervals (CI) for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 minus [-] Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)</title>
        <description>Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt; 10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move shoulder).</description>
        <time_frame>Days 1 through 14 / Year 2 (Follow-up study/NCT00500357)</time_frame>
        <population>Safety population included all participants who received the vaccine sequence 13vPnC / 23vPS / 13vPnC. N=number of participants with reactogenicity events (reported Yes for at least 1 day or No for all days); (n)=number of participants with known values for 13vPnC / 23vPS / 13vPnC (Vax 3). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up/NCT00500357)</title>
            <description>Administered 13vPnC 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672 (6115A1-500). Administered 13vPnC 0.5 mL IM at Year 2 (Vax 3) in follow-up study/NCT00500357 (6115A1-3009).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)</title>
          <description>Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt; 10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move shoulder).</description>
          <population>Safety population included all participants who received the vaccine sequence 13vPnC / 23vPS / 13vPnC. N=number of participants with reactogenicity events (reported Yes for at least 1 day or No for all days); (n)=number of participants with known values for 13vPnC / 23vPS / 13vPnC (Vax 3). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)</title>
        <description>Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius [C]); Mild (≥38 but &lt;38.5 degrees C); Moderate (≥38.5 but &lt;39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Aggravated muscle pain, New joint pain, and Aggravated joint pain.</description>
        <time_frame>Days 1 through 14 / Year 2 (Follow-up study/NCT00500357)</time_frame>
        <population>Safety population; N=number of participants with reactogenicity events (reported Yes for at least 1 day or No for all days); (n)=number of participants with known values for 13vPnC / 23vPS / 13vPnC (Vax 3). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up/NCT00500357)</title>
            <description>Administered 13vPnC 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672 (6115A1-500). Administered 13vPnC 0.5 mL IM at Year 2 (Vax 3) in follow-up study/NCT00500357 (6115A1-3009).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)</title>
          <description>Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius [C]); Mild (≥38 but &lt;38.5 degrees C); Moderate (≥38.5 but &lt;39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Aggravated muscle pain, New joint pain, and Aggravated joint pain.</description>
          <population>Safety population; N=number of participants with reactogenicity events (reported Yes for at least 1 day or No for all days); (n)=number of participants with known values for 13vPnC / 23vPS / 13vPnC (Vax 3). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any ≥38 degrees C (n=81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild ≥38 but &lt;38.5 degrees C (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate ≥38.5 but &lt;39 degrees C (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe ≥39 but ≤40 degrees C (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potentially life-threatening &gt;40 degrees C (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>Month 1 / Year 1 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)</time_frame>
        <population>Evaluable Immunogenicity population; N=number of participants with a determinate antibody titer for the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 23vPS (Vax 2 Core Study/NCT00269672)</title>
            <description>13vPnC 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672 (6115A1-500).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357)</title>
            <description>13vPnC 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) core study/NCT00269672. Administered 13vPnC 0.5mL IM at Year 2 (Vax 3) in follow-up study/NCT00500357 (6115A1-3009).</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable Immunogenicity population; N=number of participants with a determinate antibody titer for the specified serotype.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184" lower_limit="136.2" upper_limit="249.2"/>
                    <measurement group_id="O2" value="81" lower_limit="58.3" upper_limit="112.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" lower_limit="102.2" upper_limit="168.9"/>
                    <measurement group_id="O2" value="104" lower_limit="81.5" upper_limit="132.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1457" lower_limit="1092.8" upper_limit="1942.2"/>
                    <measurement group_id="O2" value="1406" lower_limit="1098.1" upper_limit="1799.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326" lower_limit="228.4" upper_limit="464.0"/>
                    <measurement group_id="O2" value="219" lower_limit="153.6" upper_limit="312.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1732" lower_limit="1163.1" upper_limit="2580.0"/>
                    <measurement group_id="O2" value="3443" lower_limit="2678.7" upper_limit="4425.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1862" lower_limit="1333.5" upper_limit="2600.7"/>
                    <measurement group_id="O2" value="2505" lower_limit="1798.8" upper_limit="3488.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1292" lower_limit="925.2" upper_limit="1803.5"/>
                    <measurement group_id="O2" value="351" lower_limit="224.5" upper_limit="550.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="624" lower_limit="371.0" upper_limit="1051.1"/>
                    <measurement group_id="O2" value="267" lower_limit="153.9" upper_limit="463.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="808" lower_limit="599.4" upper_limit="1089.7"/>
                    <measurement group_id="O2" value="557" lower_limit="399.0" upper_limit="778.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1753" lower_limit="1214.9" upper_limit="2528.5"/>
                    <measurement group_id="O2" value="1452" lower_limit="1049.6" upper_limit="2009.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="756" lower_limit="581.2" upper_limit="983.9"/>
                    <measurement group_id="O2" value="511" lower_limit="408.5" upper_limit="639.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="901" lower_limit="689.1" upper_limit="1177.3"/>
                    <measurement group_id="O2" value="527" lower_limit="369.1" upper_limit="752.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484" lower_limit="323.7" upper_limit="723.6"/>
                    <measurement group_id="O2" value="731" lower_limit="499.0" upper_limit="1071.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>2.84</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95 %confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion as a basis for comparison).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)</title>
        <description>Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
        <time_frame>Month 1 / Year 0 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)</time_frame>
        <population>Evaluable Immunogenicity population; N=number of participants with a determinate antibody concentration for the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Vax 1 Core Study/NCT00269672)</title>
            <description>13vPnC 0.5 mL IM at Year 0 (Vax 1) in core study/NCT00269672 (6115A1-500).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357)</title>
            <description>13vPnC 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672. Administered 13vPnC 0.5mL IM at Year 2 (Vax 3) in follow-up study/NCT00500357 (6115A1-3009).</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)</title>
          <description>Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
          <population>Evaluable Immunogenicity population; N=number of participants with a determinate antibody concentration for the specified serotype.</population>
          <units>geometric mean concentration (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.67" lower_limit="5.48" upper_limit="10.72"/>
                    <measurement group_id="O2" value="4.99" lower_limit="4.06" upper_limit="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" lower_limit="2.04" upper_limit="3.33"/>
                    <measurement group_id="O2" value="1.35" lower_limit="1.12" upper_limit="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" lower_limit="3.40" upper_limit="6.43"/>
                    <measurement group_id="O2" value="2.96" lower_limit="2.30" upper_limit="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.51" lower_limit="13.92" upper_limit="27.36"/>
                    <measurement group_id="O2" value="6.33" lower_limit="5.08" upper_limit="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.12" lower_limit="6.70" upper_limit="12.42"/>
                    <measurement group_id="O2" value="8.22" lower_limit="6.30" upper_limit="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.03" lower_limit="9.11" upper_limit="18.62"/>
                    <measurement group_id="O2" value="10.32" lower_limit="8.10" upper_limit="13.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" lower_limit="5.45" upper_limit="8.81"/>
                    <measurement group_id="O2" value="5.02" lower_limit="4.23" upper_limit="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.56" lower_limit="8.68" upper_limit="15.40"/>
                    <measurement group_id="O2" value="5.77" lower_limit="4.70" upper_limit="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.51" lower_limit="12.70" upper_limit="24.13"/>
                    <measurement group_id="O2" value="13.34" lower_limit="10.67" upper_limit="16.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.59" lower_limit="15.35" upper_limit="27.62"/>
                    <measurement group_id="O2" value="7.82" lower_limit="6.39" upper_limit="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.52" lower_limit="22.14" upper_limit="39.36"/>
                    <measurement group_id="O2" value="17.80" lower_limit="14.67" upper_limit="21.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.39" lower_limit="9.47" upper_limit="18.92"/>
                    <measurement group_id="O2" value="8.55" lower_limit="6.60" upper_limit="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.16" lower_limit="7.06" upper_limit="14.64"/>
                    <measurement group_id="O2" value="7.73" lower_limit="5.77" upper_limit="10.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: GMFR was calculated using all participants with available data from both the Vax 1 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)</title>
        <description>Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
        <time_frame>Month 1 / Year 1 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)</time_frame>
        <population>Evaluable Immunogenicity population; N=number of participants with a determinate antibody concentration for the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 23vPS (Vax 2 Core Study/NCT00269672)</title>
            <description>13vPnC 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672 (6115A1-500).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357)</title>
            <description>13vPnC 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) core study/NCT00269672. Administered 13vPnC 0.5mL IM at Year 2 (Vax 3) in follow-up study/NCT00500357 (6115A1-3009).</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)</title>
          <description>Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
          <population>Evaluable Immunogenicity population; N=number of participants with a determinate antibody concentration for the specified serotype.</population>
          <units>geometric mean concentration (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.29" lower_limit="5.96" upper_limit="8.93"/>
                    <measurement group_id="O2" value="4.99" lower_limit="4.06" upper_limit="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" lower_limit="2.01" upper_limit="3.01"/>
                    <measurement group_id="O2" value="1.36" lower_limit="1.13" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" lower_limit="3.03" upper_limit="5.11"/>
                    <measurement group_id="O2" value="2.96" lower_limit="2.30" upper_limit="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.29" lower_limit="7.37" upper_limit="11.71"/>
                    <measurement group_id="O2" value="6.33" lower_limit="5.08" upper_limit="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.51" lower_limit="4.25" upper_limit="7.15"/>
                    <measurement group_id="O2" value="8.22" lower_limit="6.30" upper_limit="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.67" lower_limit="7.47" upper_limit="12.53"/>
                    <measurement group_id="O2" value="10.32" lower_limit="8.10" upper_limit="13.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.41" lower_limit="6.07" upper_limit="9.04"/>
                    <measurement group_id="O2" value="5.02" lower_limit="4.23" upper_limit="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.60" lower_limit="7.68" upper_limit="12.00"/>
                    <measurement group_id="O2" value="5.77" lower_limit="4.70" upper_limit="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.67" lower_limit="17.89" upper_limit="28.72"/>
                    <measurement group_id="O2" value="13.34" lower_limit="10.67" upper_limit="16.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.66" lower_limit="9.66" upper_limit="14.07"/>
                    <measurement group_id="O2" value="7.82" lower_limit="6.39" upper_limit="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.78" lower_limit="18.47" upper_limit="28.11"/>
                    <measurement group_id="O2" value="17.80" lower_limit="14.67" upper_limit="21.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.82" lower_limit="11.97" upper_limit="20.91"/>
                    <measurement group_id="O2" value="8.55" lower_limit="6.60" upper_limit="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.27" lower_limit="5.52" upper_limit="9.57"/>
                    <measurement group_id="O2" value="7.73" lower_limit="5.77" upper_limit="10.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: GMFR was calculated using all participants with available data from both the Vax 2 and Vax 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline / Day 1 up to 43 days postvaccination. Local Reactions and Systemic Events assessed within 14 days of vaccination.</time_frame>
      <desc>An Adverse Event (AE) term may be reported as both a serious and non-serious AE, but are distinct events. AE may = serious for 1 subject and = non-serious for another subject or subject may have experienced both a serious and non-serious episode of the same event.</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study)</title>
          <description>Administered 13vPnC 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672 (6115A1-500). Administered 13vPnC 0.5 mL IM at Year 2 (Vax 3) in follow-up study/NCT00500357 (6115A1-3009).
For 13vPnC / 23vPS / 13vPnC (Vax 3 follow-up study) Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=7; systematic (solicited) Any Local Reactions N=41; systematic (solicited) Any Systemic Events N=46.</description>
        </group>
        <group group_id="E2">
          <title>13vPnC+AlPO4 (After Vax 1 Core Study)</title>
          <description>Administered 13vPnC+AlPO4 0.5 mL IM at Year 0 (Vax 1) in core study/NCT00269672 (6115A1-500). Events reported Day 1 up to Day 29 postvaccination.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC-AlPO4 (After Vax 1 Core Study)</title>
          <description>Administered 13vPnC-AlPO4 0.5 mL IM at Year 0 (Vax 1) in core study/NCT00269672 (6115A1-500). Events reported Day 1 up to Day 29 postvaccination.</description>
        </group>
        <group group_id="E4">
          <title>23vPS (After Vax 1 Core Study)</title>
          <description>Administered 23vPS 0.5 mL IM at Year 0 (Vax 1) in core study/NCT00269672 (6115A1-500). Events reported Day 1 up to Day 29 postvaccination.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC+AlPO4/13vPnC+AlPO4 (After Vax 2 Core Study)</title>
          <description>Administered 13vPnC + AlPO4 0.5 mL IM at Year 0 (Vax 1) followed by 13vPnC+AlPO4 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672 (6115A1-500). Events reported Day 1 up to Day 29 postvaccination.</description>
        </group>
        <group group_id="E6">
          <title>13vPnC+AlPO4/23vPS (After Vax 2 Core Study)</title>
          <description>Administered 13vPnC+AlPO4 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672 (6115A1-500). Events reported Day 1 up to Day 29 postvaccination.</description>
        </group>
        <group group_id="E7">
          <title>13vPnC-AlPO4/23vPS (After Vax 2 Core Study)</title>
          <description>Administered 13vPnC-AlPO4 0.5 mL IM at Year 0 (Vax 1) followed by 23vPS 0.5 mL IM at Year 1 (Vax 2) in core study/NCT00269672 (6115A1-500). Events reported Day 1 up to Day 29 postvaccination.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="76" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dacryoadenitis acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Anal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (any) ≥ 38 degrees Celsius (C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (mild) ≥ 38 but &lt;38.5 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (moderate) ≥ 38.5 but &lt;39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (severe) ≥ 39 but ≤40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (potentially life-threatening) &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Decreased appetitie</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site movement impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site joint movement impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Local reactions">Redness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lentigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

